Keyphrases
Agitation
23%
Alzheimer's Disease
16%
Alzheimer's Disease Patient
20%
Antipsychotics
35%
Blind Comparison
14%
Clinical Characteristics
14%
Clinical Global Impression Scale
15%
Clozapine
14%
Comorbid
14%
Dementia
19%
Depressive Episode
14%
Donepezil
29%
Elderly Patients
70%
Electroconvulsive Therapy
14%
Erotomania
14%
Folic Acid Deficiency
14%
Forequarter Amputation
14%
Heat Shock Protein 60 (HSP60)
14%
Heat Shock Proteins
17%
Hospitalization Rate
14%
Imaging Characteristics
14%
Influenza Complications
14%
Late-onset Psychosis
29%
Major Depressive Disorder
25%
Negative Sign
18%
Negative Symptoms
16%
Neuroblastoma Cell Line
18%
Obstetric Complications
14%
Olanzapine
14%
Older Patients
14%
Orchiectomy
14%
Palliation
14%
Paroxetine
14%
Patients at Risk
14%
Patients with Schizophrenia
100%
Placebo-controlled Study
29%
Positive Symptoms
16%
Psychiatric Patients
17%
Quetiapine
29%
Schizophrenia
66%
Schizophrenia Depression
17%
Schizophrenic Patients
52%
Second Trimester
14%
Serum Factors
14%
Severe Mental Illness
14%
Symptom Scale
16%
Treatment-resistant Depression
14%
Typical Antipsychotics
16%
Venlafaxine
29%
Ziprasidone
14%
Pharmacology, Toxicology and Pharmaceutical Science
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
11%
Adverse Event
9%
Alzheimer's Disease
34%
Antidepressant
5%
Antipsychotic
12%
Anxiety Disorder
5%
Atypical Antipsychotics
6%
Cholinesterase Inhibitor
5%
Clozapine
14%
Cognitive Defect
7%
Depressive Disorder
14%
Donepezil
29%
Dopamine Receptor Blocking Agent
7%
DSM-IV
9%
Folic Acid Deficiency
14%
Infection
14%
Negative Syndrome
16%
Olanzapine
14%
Paroxetine
14%
Placebo
10%
Placebo-Controlled Study
29%
Positive Syndrome
16%
Quetiapine
29%
Receptor
7%
Serotonin
7%
Side Effect
7%
Social Phobia
14%
Sulpiride
11%
Tolerability
6%
Typical Antipsychotic
20%
Venlafaxine
29%
Ziprasidone
14%
Zuclopenthixol
7%